Trial · NCT02014584
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Erectile dysfunction | Reproductive system and breast disorders | Placebo (DB) | 3 | 59 | |
| other | Erectile dysfunction | Reproductive system and breast disorders | Dutasteride 0.5 mg (DB) | 7 | 58 | |
| other | Erectile dysfunction | Reproductive system and breast disorders | Placebo (DB)/Dutasteride 0.5 mg (OL) | 1 | 49 | |
| other | Erectile dysfunction | Reproductive system and breast disorders | Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 0 | 48 | |
| other | Erectile dysfunction | Reproductive system and breast disorders | Combined: Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 7 | 48 | |
| other | Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Placebo (DB) | 2 | 59 | |
| other | Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Dutasteride 0.5 mg (DB) | 4 | 58 | |
| other | Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Placebo (DB)/Dutasteride 0.5 mg (OL) | 0 | 49 | |
| other | Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 4 | 48 | |
| other | Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Combined: Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 8 | 48 | |
| serious | Hypokalaemia | Metabolism and nutrition disorders | Placebo (DB) | 0 | 59 | |
| serious | Hypokalaemia | Metabolism and nutrition disorders | Dutasteride 0.5 mg (DB) | 1 | 58 | |
| serious | Hypokalaemia | Metabolism and nutrition disorders | Placebo (DB)/Dutasteride 0.5 mg (OL) | 0 | 49 | |
| serious | Hypokalaemia | Metabolism and nutrition disorders | Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 0 | 48 | |
| serious | Hypokalaemia | Metabolism and nutrition disorders | Combined: Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 1 | 48 | |
| serious | Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | Placebo (DB) | 1 | 59 | |
| serious | Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | Dutasteride 0.5 mg (DB) | 0 | 58 | |
| serious | Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | Placebo (DB)/Dutasteride 0.5 mg (OL) | 1 | 49 | |
| serious | Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 0 | 48 | |
| serious | Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | Combined: Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | 0 | 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02014584/events